肿瘤CD276表达对前列腺癌浸润免疫细胞及临床病理特征的影响
本研究通过转录组和蛋白质组分析鉴定CD276为免疫治疗潜在靶点,体内外实验证实CD276敲低可增强CD8+ T细胞向免疫微环境浸润,前列腺癌样本免疫组化分析进一步确认相同发现,结论认为CD276抑制前列腺癌中CD8+ T细胞的富集。
要点
- CD276被鉴定为调节免疫微环境的关键分子。
- CD276敲低增强CD8+ T细胞向免疫微环境浸润。
- 前列腺癌样本免疫组化分析证实相同发现。
核心结论
- CD276被发现在前列腺癌中抑制CD8+ T细胞的富集。
- 因此,CD276抑制剂可能是免疫治疗的潜在靶点。
研究设计与样本
- 采用转录组和蛋白质组分析鉴定CD276为免疫治疗潜在靶点。
- 通过体内和体外实验确认其作为免疫治疗效应潜在介质的作用。
- 对前列腺癌样本进行免疫组化分析。
主要发现
- 多组学分析提示CD276被鉴定为调节免疫微环境的关键分子。
- 体内实验显示CD276敲低增强CD8+ T细胞向免疫微环境浸润。
- 前列腺癌样本免疫组化分析进一步证实相同发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced prostate cancer (PCa) is often resistant to immunotherapy. In this study, we examined the role of CD276 in mediating immunotherapeutic effects through changes in immune cell infiltration. METHODS: Using transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. Subsequent in vivo and in vitro experiments confirmed its role as a potential mediator of immunotherapeutic effects. RESULTS: Multi-omic analysis suggested that CD276 was identified as a key molecule regulating the immune microenvironment (IM). In vivo experiments revealed that CD276 knockdown was found to enhance CD8+ T cell infiltration into the IM. Immunohistochemical analysis of PCa samples further confirmed the same findings. CONCLUSION: CD276 was found to inhibit the enrichment of CD8+ T cells in PCa. Thus, CD276 inhibitors may be potential targets for immunotherapy.
引用
- Liu J, Kadier A, Guo Y, et al. Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37380802. doi:10.1038/s41391-023-00690-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。